Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-27T20:42:31.776Z Has data issue: false hasContentIssue false
  • English
  • Français

The clinical significance of atypical antipsychotics

Published online by Cambridge University Press:  18 September 2015

J.A. Den Boer ,
H.G.M. Westenberg ,
J.W. Louwerens  and
C.J. Slooff
J.A. Den Boer*
Affiliation:
psychiater en klinisch farmacoloog verbonden aan de Afdeling Biologische, Psychiatrie van het AZU
H.G.M. Westenberg
Affiliation:
psychiater en klinisch farmacoloog verbonden aan de Afdeling Biologische, Psychiatrie van het AZU
J.W. Louwerens
Affiliation:
psychiater verbonden aan de afdeling psychiatrie van het Academisch Ziekenhuis Groningen, alsmede Psychiatrisch Ziekenhuis Licht en Kracht te Assen
C.J. Slooff
Affiliation:
psychiater verbonden aan de afdeling psychiatrie van het Academisch Ziekenhuis Groningen, alsmede Psychiatrisch Ziekenhuis Licht en Kracht te Assen
*
Universitair Hoofddocent, Klinische en Biologische Psychiatrie Afdeling Biologische Psychiatric Academisch Ziekenhuis Utrecht Postbus 85500, 3508 GA Utrecht
Get access Rights & Permissions [Opens in a new window]

Summary

A concise review is given of the importance of the atypical antipsychotic drugs clozapine, sulpiride, remoxipride and raclopride. Both the concept of atypicality and the pharmacological profile of these compounds is discussed. The newly developed atypical antipsychotic remoxipride has been studied in several double blind studies. In virtually all of these studies a reduced propensity for the induction of extrapyramidal symptoms was found.

These findings implicate that atypical antipsychotics may also not induce tardive dyskinesia. In addition to the treatment of acute schizophrenia, these compounds might be of use in the treatment of treatment resistent schizophrenia (clozapine), tardive dyskinesia and psychosis during the course of Parkinson's disease.

Keywords

atypical antipsychoticsdopamine D2-receptorsschizophreniaextrapyramidal symptomsatypische antipsychoticadopamine D2-receptorenschizofrenieextrapiramidale Symptomen
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 3 , Issue 4 , December 1991 , pp. 55 - 60
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Deniker, P. Discovery of the clinical use of neuroleptics. In: Parnham, M, Bruinvels, J, eds. Discoveries in Pharmacology vol 1: Psycho- and Neuro-pharmacology. Amsterdam: Elsevier, 1983: 163–80.Google Scholar
2.Cole, J, Clyde, D. Extrapyramidal side-effects and clinical response to the phenothiazines. Rev can Biol 1961; 20: 565–74.Google Scholar
3.Arnt, J. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982; 51: 321–9.CrossRefGoogle ScholarPubMed
4.Gerlach, J, Koppelhus, P, Helweg, E, Monrad, A. Clozapine and haloperidol in a single blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta psychiat scand 1974; 40: 410–24.CrossRefGoogle Scholar
5.Fitton, A, Heel, RC. Clozapine, a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990; 40(5): 722–47.CrossRefGoogle ScholarPubMed
6.Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine in treatment resistant schizophrenics. Psychopharmacol Bull 1988; 24: 63–7.Google ScholarPubMed
7.Miller, CH, Fleischhacker, WW, Ehrmann, H, Kane, JM. Treatment of neuroleptic induced akathisia with the 5HT2 antagonist ritanserin. Psychopharm Bull 1990; 26(3): 373–6.Google ScholarPubMed
8.Creese, I. Classical and atypical antipsychotic drugs: new insights. Trends Neurosci 1983; 6: 479–81.CrossRefGoogle Scholar
9.Costall, B, Fortune, DH, Naylor, RJ, Marsden, CD, Pycock, C. Serotoninergic involvement with neuroleptic catelepsy. Neuropharmacol 1975; 14: 859–68.CrossRefGoogle Scholar
10.Bleich, A, Brown, SL, Kahn, RS, Praag, HM van. The role of serotonin in schizophrenia. Schizophr Bull 1988; 14(2): 297–315.CrossRefGoogle ScholarPubMed
11.Louwerens, JW, Coppens, HC, Korf, J, Sloof, CJ, Paans, AMG, Vaalburg, W. On the pathogenetic role of dopaminergic and serotonergic neurotransmission in longterm hospitalized psychotic patients. Schizophr Res 1990; 3(1): 52.CrossRefGoogle Scholar
12.Gerlach, J, Behnke, K, Heltberg, J, Munk-Andersen, E, Nielsen, H. Sulpiride and haloperidol in schizophrenia: A double-blind crossover study of therapeutic effect, side effects and plasma concentrations. Br J Psychiat 1985; 147: 283–8.CrossRefGoogle ScholarPubMed
13.Peselow, ED, Stanley, M. Clinical trials of benzamides in Psychiatry. In: Rotrosen, J, Stanley, M, eds. The Benzamides: Pharmacology, Neurobiology and Clinical Aspects. New York: Raven Press, 1982: 163–94.Google Scholar
14.Den Boer, JA, Westenberg, HGM, Verhoeven, WMA. Pathofysiolo-gische en therapeutische aspecten van negatieve symptomen. Tijd-schr Psychiat 1987; 29: 638–53.Google Scholar
15.Willner, P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res Rev 1986; 6: 211–24.CrossRefGoogle Scholar
16.Ogren, SO, Hall, H, Kohler, C, Magnusson, O. Neuropharmacological properties of remoxipride. Pharmacopsychiat 1988: 21:65.Google Scholar
17.Den Boer, JA, Verhoeven, WMA, Westenberg, HGM. Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia. Psychopharmacol Bull 1987; 23: 206–10.Google ScholarPubMed
18.Den Boer, JA, Ravelli, DP, Huisman, J, Ohrvik, J, Verhoeven, WMA, Westenberg, HGM. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacol 1990; 102:76–84.CrossRefGoogle ScholarPubMed
19.Chouinard, G. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J clin Psychopharmacol 1987; 7: 159–64.CrossRefGoogle ScholarPubMed
20.Chouinard, G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta psychiat scand 1990; 82 (suppl.358): 111–9.CrossRefGoogle Scholar
21.Lewander, T, Westerbergh, S-E, Morrison, D. Clinical profile of remoxipride - a combined analysis of a comparative double-blindmulticentre trial programme. Acta psychiat scand 1990; 82 (suppl 358): 92–8.CrossRefGoogle Scholar
22.Andersson, U, Nilsson, MI, Haggstrom, JE, Widerlov, E. Antidyski-netic action and pharmacokinetics of remoxipride, a substituted benzamide in elderly patients with tardive dyskinesia. Presented at the 14th CINP Congress, Florence 1984.Google Scholar
23.Köhler, C, Hall, H, Ogren, SO, Gawell, L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 1985; 34 (13): 2251–9.CrossRefGoogle ScholarPubMed
24.Farde, L, Wiesel, FA, Jansson, P, Uppfeldt, G, Wahlen, A, Sedvall, G. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacol 1988; 94: 1–7.CrossRefGoogle ScholarPubMed
25.Cooper, SJ, Doharty, MM. Remoxipride in the treatment of coexistent schizophrenia and Parkinson's Disease. Hum Psychopharmacol 1989; 4: 145–7.CrossRefGoogle Scholar